CINJ 020702: A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone and Choline Magnesium Trisalicylate in the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Trial Profile

CINJ 020702: A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone and Choline Magnesium Trisalicylate in the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2015

At a glance

  • Drugs Tetradecanoylphorbol acetate (Primary) ; Choline magnesium trisalicylate; Dexamethasone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jun 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 06 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top